IP Library Granted Patent US 8,664,366
Granted Patent B2
US 8,664,366 · App. 13/143,531 · Granted Mar 4, 2014

Fusion proteins forming trimers

Inventors: Oliver Hill (Neckarsteinach, DE); Marcus Branschaedel (Laupheim, DE); Christian Gieffers (Dossenheim, DE); Meinolf Thiemann (Schriesheim, DE)
Assignee: Apogenix GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,664,366
App. No.
13/143,531
Granted
Mar 4, 2014
Kind
B2
Abstract

The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.

Claims (16)

1. A fusion protein comprising

(i) a collectin family trimerization domain consisting of amino acid residues 221-375 of SEQ ID NO: 21, optionally further consisting of an amino acid substitution at residue 355;

(ii) a linker element; and

(iii) an effector polypeptide selected from the group consisting of a single chain antibody, an antigen binding fragment of a single chain antibody, or an antigen binding fragment of an antibody, wherein the effector polypeptide is located N-terminally of the collectin family neck region

wherein said linker element has 25 or less amino acids.

2. The fusion protein claim 1 , wherein the collectin family trimerization domain consists of the amino acid residues 221-375 of SEQ ID NO: 21.

3. The fusion protein of claim 1 , wherein the amino acid residue 355 in SEQ ID NO: 21 is optionally substituted to a polar amino acid selected from the group consisting of aspartic acid, glutamic acid, asparagine and glutamine.

4. The fusion protein of claim 1 , wherein the effector polypeptide is a single chain antibody against IL4R-alpha.

5. The fusion protein of claim 1 , wherein the linker element has the amino acid sequence of SEQ ID NO: 56, which is GSSGSSGSSGSG.

6. The fusion protein of claim 1 , wherein the linker element has the amino acid sequence of SEQ ID NO: 34, which is GSSGSSGSSGS.

7. The fusion protein of claim 1 , further comprising an N-terminal signal peptide domain.

8. The fusion protein of claim 1 , further comprising a recognition/purification domain selected from the group consisting of a strep-tag domain and a poly-His domain.

9. The fusion protein of claim 1 , wherein the effector polypeptide is a monovalent Fab fragment.

10. The fusion protein of claim 1 , wherein the effector polypeptide is a single chain variable fragment (scFv).

11. The fusion protein of claim 10 , wherein the scFv has a variable domain of a heavy chain located N-terminal to the a variable domain of a light chain.

12. A trimeric complex consisting of three identical fusion proteins of claim 1 .

Assignments (2)
CHANGE OF NAME Recorded Mar 21, 2016
From: APOGENIX GMBH
To: APOGENIX AG
Reel/Frame 038190/0226 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2011
From: HILL, OLIVER; BRANSCHAEDEL, MARCUS; GIEFFERS, CHRISTIAN; THIEMANN, MEINOLF
To: APOGENIX GMBH
Reel/Frame 026841/0084 →
Continuity (1)
Related Publication 20120041181A1 · Feb 16, 2012